TherapeuticsMD Inc. stock rises 1.45% and outperforms competitors

7 articles · Updated · MarketWatch · Apr 28

Shares closed at $2.10 on Tuesday, while the NASDAQ Composite fell 0.90% and Dow Jones dropped 0.05%.
Despite the gain, TherapeuticsMD remains 28.81% below its 52-week high of $2.95 reached in January.
Trading volume was 10,070, significantly lower than the 50-day average of 22,987, reflecting subdued investor activity.

Could activist investors target TherapeuticsMD next, given its strategic review and low valuation?

Does TXMD's low trading volume invalidate its recent outperformance against the market?

With insiders buying but financials weak, is TherapeuticsMD a value trap or a prime acquisition target?

How will the pharma M&A boom affect small royalty companies like TherapeuticsMD?

Can a lawsuit victory be the catalyst that saves TherapeuticsMD from its financial struggles?

Why is billionaire Ken Fisher doubling down on AbbVie amid industry-wide pricing pressures?